Phase 2
Completed N=9
Glenohumeral Cortisone Injection
Humeral Fractures
Source: ClinicalTrials.gov NCT04216017 ↗
Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcomePrimary: American Shoulder Elbow Society Score — 46; 87 score on a scale
Summary
The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY American Shoulder Elbow Society Score |
46; 87 | — |
| SECONDARY Visual Analogue Scale |
4; 1 | — |
Eligibility Criteria
Inclusion Criteria
1.18-90
- Proximal Humerus Fracture
- Decreased range of motion at 6 wk follow-up
- Likely to be available for follow up for 26 wks
Exclusion Criteria
- Known drug allergy to kenalog or lidocaine
- Unable to complete functional outcome
- Pregnant Women
Data sourced from ClinicalTrials.gov (NCT04216017). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.